Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Nature Publishing Group Country of Publication: England NLM ID: 0410462 Publication Model: Print Cited Medium: Internet ISSN: 1476-4687 (Electronic) Linking ISSN: 00280836 NLM ISO Abbreviation: Nature Subsets: MEDLINE
    • Publication Information:
      Publication: Basingstoke : Nature Publishing Group
      Original Publication: London, Macmillan Journals ltd.
    • Subject Terms:
      Protein Multimerization* ; Signal Transduction*/drug effects; Janus Kinase 2/*antagonists & inhibitors ; Janus Kinase 2/*metabolism ; Myeloproliferative Disorders/*drug therapy ; STAT Transcription Factors/*metabolism; Animals ; Cell Line ; Disease Models, Animal ; Drug Resistance, Neoplasm/drug effects ; Enzyme Activation/drug effects ; Gene Knockdown Techniques ; Granulocytes/drug effects ; Granulocytes/enzymology ; Granulocytes/metabolism ; HSP90 Heat-Shock Proteins/antagonists & inhibitors ; HSP90 Heat-Shock Proteins/metabolism ; Humans ; Janus Kinase 1/biosynthesis ; Janus Kinase 1/deficiency ; Janus Kinase 1/genetics ; Janus Kinase 1/metabolism ; Janus Kinase 2/deficiency ; Janus Kinase 2/genetics ; Mice ; Myeloproliferative Disorders/enzymology ; Myeloproliferative Disorders/metabolism ; Myeloproliferative Disorders/pathology ; Phosphorylation ; Protein Biosynthesis ; RNA Interference ; TYK2 Kinase/biosynthesis ; TYK2 Kinase/deficiency ; TYK2 Kinase/genetics ; TYK2 Kinase/metabolism
    • Abstract:
      The identification of somatic activating mutations in JAK2 (refs 1–4) and in the thrombopoietin receptor gene (MPL) in most patients with myeloproliferative neoplasm (MPN) led to the clinical development of JAK2 kinase inhibitors. JAK2 inhibitor therapy improves MPN-associated splenomegaly and systemic symptoms but does not significantly decrease or eliminate the MPN clone in most patients with MPN. We therefore sought to characterize mechanisms by which MPN cells persist despite chronic inhibition of JAK2. Here we show that JAK2 inhibitor persistence is associated with reactivation of JAK–STAT signalling and with heterodimerization between activated JAK2 and JAK1 or TYK2, consistent with activation of JAK2 in trans by other JAK kinases. Further, this phenomenon is reversible: JAK2 inhibitor withdrawal is associated with resensitization to JAK2 kinase inhibitors and with reversible changes in JAK2 expression. We saw increased JAK2 heterodimerization and sustained JAK2 activation in cell lines, in murine models and in patients treated with JAK2 inhibitors. RNA interference and pharmacological studies show that JAK2-inhibitor-persistent cells remain dependent on JAK2 protein expression. Consequently, therapies that result in JAK2 degradation retain efficacy in persistent cells and may provide additional benefit to patients with JAK2-dependent malignancies treated with JAK2 inhibitors.
    • Comments:
      Comment in: Nat Rev Cancer. 2012 Sep;12(9):583. (PMID: 22918412)
    • References:
      N Engl J Med. 2010 Sep 16;363(12):1117-27. (PMID: 20843246)
      PLoS Med. 2005 Jan;2(1):e17. (PMID: 15696205)
      Science. 2007 May 18;316(5827):1039-43. (PMID: 17463250)
      N Engl J Med. 2001 Apr 5;344(14):1031-7. (PMID: 11287972)
      N Engl J Med. 2005 Apr 28;352(17):1779-90. (PMID: 15858187)
      N Engl J Med. 2009 Sep 3;361(10):947-57. (PMID: 19692680)
      PLoS Med. 2006 Jul;3(7):e270. (PMID: 16834459)
      Lancet. 2005 Mar 19-25;365(9464):1054-61. (PMID: 15781101)
      Science. 2001 Aug 3;293(5531):876-80. (PMID: 11423618)
      Nature. 2005 Apr 28;434(7037):1144-8. (PMID: 15793561)
      N Engl J Med. 2010 Aug 26;363(9):809-19. (PMID: 20818844)
      J Clin Invest. 2010 Oct;120(10):3578-93. (PMID: 20852385)
      Cell. 2003 Mar 21;112(6):831-43. (PMID: 12654249)
      Cell. 2010 Apr 2;141(1):69-80. (PMID: 20371346)
      Cancer Cell. 2002 Aug;2(2):117-25. (PMID: 12204532)
      J Biol Chem. 2005 Jun 17;280(24):22788-92. (PMID: 15863514)
      Cell. 1998 May 1;93(3):385-95. (PMID: 9590173)
      Nature. 2010 Dec 16;468(7326):973-7. (PMID: 21107323)
      Cancer Discov. 2012 Jun;2(6):512-523. (PMID: 22684457)
      J Clin Oncol. 2011 Mar 1;29(7):789-96. (PMID: 21220608)
      Nature. 2007 Aug 2;448(7153):553-60. (PMID: 17603471)
      Blood. 2009 Dec 3;114(24):5024-33. (PMID: 19828702)
      N Engl J Med. 2009 Sep 3;361(10):958-67. (PMID: 19692684)
      J Med Chem. 2006 Jan 12;49(1):381-90. (PMID: 16392823)
      Leukemia. 2008 Apr;22(4):740-7. (PMID: 18079739)
      N Engl J Med. 2005 Feb 24;352(8):786-92. (PMID: 15728811)
      Blood. 2010 Apr 8;115(14):2919-27. (PMID: 20154217)
      Nature. 2010 Dec 16;468(7326):968-72. (PMID: 21107320)
      Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9414-8. (PMID: 19470474)
      Curr Opin Genet Dev. 2007 Feb;17(1):8-14. (PMID: 17208428)
      PLoS Med. 2005 Mar;2(3):e73. (PMID: 15737014)
      J Biol Chem. 2007 Oct 19;282(42):30985-96. (PMID: 17726028)
    • Grant Information:
      P30 CA016672 United States CA NCI NIH HHS; R01 CA151949 United States CA NCI NIH HHS; United States HHMI Howard Hughes Medical Institute; 1R01CA151949-01 United States CA NCI NIH HHS
    • Molecular Sequence:
      GEO GSE38335
    • Accession Number:
      0 (HSP90 Heat-Shock Proteins)
      0 (STAT Transcription Factors)
      EC 2.7.10.2 (Janus Kinase 1)
      EC 2.7.10.2 (Janus Kinase 2)
      EC 2.7.10.2 (TYK2 Kinase)
    • Publication Date:
      Date Created: 20120724 Date Completed: 20121017 Latest Revision: 20211021
    • Publication Date:
      20231215
    • Accession Number:
      PMC3991463
    • Accession Number:
      10.1038/nature11303
    • Accession Number:
      22820254